DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-333/S-008 & 009

Shire Pharmaceutical Development Inc.
Attention: Catherine Symington
1801 Research Blvd., Suite 500
Rockville, MD 20850

Dear Ms. Symington:

Please refer to your supplemental new drug application dated March 12, 2004, received March 12, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Agrylin (anagrelide hydrochloride) Capsules.

Upon preliminary review of your submission, we found that it provided for two separate changes to your NDA. Accordingly, the submission dated March 12, 2004, received March 12, 2004 was administratively separated as follows:

Name of Drug: Agrylin (anagrelide hydrochloride) Capsules

Supplement: S-008

Provides for labeling changes based on results of the SPD422-202 clinical study report (CSR) submitted in response to the Written Request dated March 8, 2004, for a pediatric study of Agrylin® (anagrelide hydrochloride) Capsules.

Supplement: S-009

Provides for changes to the PRECAUTIONS section, Drug Interactions subsection of the label based on two anagrelide drug-drug interaction studies.

We acknowledge receipt of your submissions dated May 10, July 14, August 19, August 26, and September 8, September 9, December 9, and December 10, 2004.

Your submission of December 10, 2004 constituted a complete response to our September 9, 2004 action letter for S-009.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) and submitted labeling (package insert submitted December 10, 2004). Please submit the FPL electronically according to the guidance for industry titled, "Providing Regulatory Submissions in Electronic Format – NDA." Alternatively, you may submit 20 paper copies of

the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-333/S-008 and S-009." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ryan Barraco, Consumer Safety Officer, at 301-443-8017.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H
Acting Director
Division of Gastrointestinal & Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Joyce Korvick

12/10/04 03:45:00 PM